Glutamate-mediated signaling and autism spectrum disorders: Emerging treatment targets

Current Pharmaceutical Design

Volumn 20, Issue 32, 2014, Pages 5186-5193

  Yang, Pinchen ^a   Chang, Chen Lin ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c MEIHO UNIVERSITY   (Taiwan)

Author keywords

Autism spectrum disorders; Glutamate; Treatment

Indexed keywords

AMPA RECEPTOR; ANKYRIN; CELL ADHESION MOLECULE; CYCLOSERINE; DEXTRO SERINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; MEMANTINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUREXIN; NEUROLIGIN; OXYTOCIN; PROTEIN SH3; RAPASTINEL; RILUZOLE; SARCOSINE;

ANIMAL MODEL; ARTICLE; AUTISM; CLINICAL TRIAL (TOPIC); HUMAN; LEARNING; MEMORY; MOLECULARLY TARGETED THERAPY; MONOSYNAPTIC PATHWAY; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RARE DISEASE; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; SYSTEMATIC REVIEW (TOPIC); ANIMAL; AUTISM SPECTRUM DISORDER; CYTOLOGY; DRUG DESIGN; METABOLISM; PHYSIOLOGY; PLURIPOTENT STEM CELL;

ANIMALS; AUTISM SPECTRUM DISORDER; DRUG DESIGN; GLUTAMIC ACID; HUMANS; MOLECULAR TARGETED THERAPY; NEURONAL PLASTICITY; PLURIPOTENT STEM CELLS; RECEPTORS, GLUTAMATE; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 84926294610     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666140110120725     Document Type: Article

References (94)

1. Kim YS, Leventhal BL, Koh YJ, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry 2011; 168: 904-12.
2. Schaaf CP, Zoghbi HY. Solving the autism puzzle a few pieces at a time. Neuron. 2011; 70: 806-8..
3. Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res. 2011; 1380: 42-77..
4. Toro R, Konyukh M, Delorme R, et al. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet. 2010; 26: 363-72.
5. van Spronsen M, Hoogenraad CC. Synapse pathology in psychiatric and neurologic disease. Curr Neurol Neurosci Rep. 2010; 10: 207-14.
6. Sheng M, Hoogenraad CC. The postsynaptic architecture of excitatory synapses: a more quantitative view. Annu Rev Biochem. 2007; 76: 823-47.
7. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology [Berl]. 2005; 179: 4-29..
8. Monaghan DT, Yao D, Cotman CW. L-[3H]Glutamate binds to kainate-, NMDA-and AMPA-sensitive binding sites: an autoradiographic analysis. Brain Res. 1985; 340: 378-83.
9. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci. 2007; 8: 413-26.
10. Greer PL, Greenberg ME. From synapse to nucleus: calciumdependent gene transcription in the control of synapse development and function. Neuron. 2008; 59: 846-60.
11. Wang K, Zhang H, Ma D, et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature. 2009; 459: 528-33.
12. Lesage A, Steckler T. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness. Eur J Pharmacol. 2010; 639: 2-16.
13. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, Olney JW. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol. 1995; 355: 455-69.
14. Dolen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile X. Pharmacol Ther. 2010; 127: 78-93.
15. Betancur C, Sakurai T, Buxbaum JD. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci. 2009; 32: 402-12.
16. Chih B, Engelman H, Scheiffele P. Control of excitatory and inhibitory synapse formation by neuroligins. Science. 2005; 307: 1324-8.
17. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet. 2008; 9: 341-55.
18. Varoqueaux F, Aramuni G, Rawson RL, et al. Neuroligins determine synapse maturation and function. Neuron. 2006; 51: 741-54.
19. Sudhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008; 455: 903-11.
20. Alarcon M, Abrahams BS, Stone JL, et al. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autismsusceptibility gene. Am J Hum Genet. 2008; 82: 150-9.
21. Penagarikano O, Geschwind DH. What does CNTNAP2 reveal about autism spectrum disorder? Trends Mol Med. 2012; 18: 156-63.
22. Graf ER, Zhang X, Jin SX, Linhoff MW, Craig AM. Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins. Cell. 2004; 119: 1013-26.
23. Kattenstroth G, Tantalaki E, Sudhof TC, Gottmann K, Missler M. Postsynaptic N-methyl-D-aspartate receptor function requires alpha-neurexins. Proc Natl Acad Sci U S A. 2004; 101: 2607-12.
24. Moessner R, Marshall CR, Sutcliffe JS, et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet. 2007; 81: 1289-97.
25. Naisbitt S, Kim E, Tu JC, et al. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron. 1999; 23: 569-82..
26. Durand CM, Perroy J, Loll F, et al. SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry. 2012; 17: 71-84.
27. Bangash MA, Park JM, Melnikova T, et al. Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism. Cell. 2011; 145: 758-72.
28. Peca J, Feliciano C, Ting JT, et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature. 2011; 472: 437-42..
29. Verpelli C, Dvoretskova E, Vicidomini C, et al. Importance of Shank3 protein in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapses. J Biol Chem. 2011; 286: 34839-50.
30. Kelleher RJ, 3rd, Bear MF. The autistic neuron: troubled translation? Cell. 2008; 135: 401-6.
31. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991; 65: 905-14.
32. Greenough WT, Klintsova AY, Irwin SA, Galvez R, Bates KE, Weiler IJ. Synaptic regulation of protein synthesis and the fragile X protein. Proc Natl Acad Sci U S A. 2001; 98: 7101-6.
33. Pieretti M, Zhang FP, Fu YH, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991; 66: 817-22.
34. Godfraind JM, Reyniers E, De Boulle K, et al. Long-term potentiation in the hippocampus of fragile X knockout mice. Am J Med Genet. 1996; 64: 246-51.
35. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002; 99: 7746-50.
36. Brown V, Jin P, Ceman S, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001; 107: 477-87.
37. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004; 27: 370-7.
38. Dolen G, Osterweil E, Rao BS, et al. Correction of fragile X syndrome in mice. Neuron. 2007; 56: 955-62.
39. de Vrij FM, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis. 2008; 31: 127-32.
40. McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron. 2005; 45: 753-64.
41. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005; 49: 1053-66.
42. Berry-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009; 46: 266-71.
43. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Science translational medicine. 2011; 3: 64ra1.
44. Smalley SL. Autism and tuberous sclerosis. J Autism Dev Disord. 1998; 28: 407-14.
45. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord. 2003; 33: 365-82.
46. Ehninger D, Silva AJ. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends Mol Med. 2011; 17: 78-87.
47. Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol. 2007; 17: 103-11.
48. Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 2011; 480: 63-8.
49. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A. 2010; 107: 11591-6.
50. Ramocki MB, Zoghbi HY. Failure of neuronal homeostasis results in common neuropsychiatric phenotypes. Nature. 2008; 455: 912-8.
51. Institute for Medicine (US) Forum on neuroscience and Nervous System Disorder. Glutamate-related biomarkers in drug development for disorders of the nervous system.Workshop Summary, Washington DC: National Academic Press; 2011.
52. Tsai GE, Falk WE, Gunther J, Coyle JT. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999; 156: 467-9.
53. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. d-Cycloserine enhances implicit memory in Alzheimer patients. Neurology. 1996; 46: 420-4.
54. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of Dcycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999; 56: 21-7.
55. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007; 164: 1593-602.
56. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008; 165: 335-41.
57. Kushner MG, Kim SW, Donahue C, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007; 62: 835-8.
58. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004; 61: 1136-44.
59. Storch EA, Murphy TK, Goodman WK, et al. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010; 68: 1073-6.
60. Modi ME, Young LJ. D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders. Biol Psychiatry. 2011; 70: 298-304.
61. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004; 161: 2115-7.
62. Shimazaki T, Kaku A, Chaki S. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology [Berl]. 2010; 209: 263-70.
63. Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006; 60: 645-9.
64. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or Dserine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005; 62: 1196-204.
65. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004; 55: 452-6.
66. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998; 44: 1081-9.
67. Moskal JR, Burgdorf J, Kroes RA, Brudzynski SM, Panksepp J. A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism. Neurosci Biobehav Rev. 2011; 35: 1982-8.
68. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348: 1333-41.
69. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006; 14: 704-15.
70. de Lucena D, Fernandes BS, Berk M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 2009; 70: 1416-23.
71. Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology [Berl]. 2001; 157: 1-10.
72. Owley T, Salt J, Guter S, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006; 16: 517-24.
73. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology [Berl]. 2007; 191: 141-7.
74. Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2012: 1-7..
75. Urbani A, Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci. 2000; 12: 3567-74.
76. Frizzo ME, Dall'Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol. 2004; 24: 123-8.
77. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007; 17: 761-7.
78. Wink LK, Erickson CA, Stigler KA, McDougle CJ. Riluzole in autistic disorder. J Child Adolesc Psychopharmacol. 2011; 21: 375-9.
79. Lee HJ, Macbeth AH, Pagani JH, Young WS, 3rd. Oxytocin: the great facilitator of life. Progress in neurobiology. 2009; 88: 127-51.
80. Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007; 61: 498-503.
81. Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012; 3: 16..
82. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010; 67: 692-4.
83. Domes G, Heinrichs M, Kumbier E, Grossmann A, Hauenstein K, Herpertz SC. Effects of Intranasal Oxytocin on the Neural Basis of Face Processing in Autism Spectrum Disorder. Biol Psychiatry. 2013. Epub 2013/03/21.
84. Ninan I. Oxytocin suppresses basal glutamatergic transmission but facilitates activity-dependent synaptic potentiation in the medial prefrontal cortex. J Neurochem. 2011; 119: 324-31.
85. Basu AC, Tsai GE, Ma CL, et al. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry. 2009; 14: 719-27..
86. Tsai G, Ralph-Williams RJ, Martina M, et al. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci U S A. 2004; 101: 8485-90.
87. Balu DT, Coyle JT. Glutamate receptor composition of the postsynaptic density is altered in genetic mouse models of NMDA receptor hypo-and hyperfunction. Brain Res. 2011; 1392: 1-7.
88. Buxbaum JD, Betancur C, Bozdagi O, Dorr NP, Elder GA, Hof PR. Optimizing the phenotyping of rodent ASD models: Enrichment analysis of mouse and human neurobiological phenotypes associated with high-risk autism genes identifies morphological, electrophysiological, neurological, and behavioral features. Mol Autism. 2012; 3: 1.
89. McClellan J, King MC. Genetic heterogeneity in human disease. Cell. 2010; 141: 210-7.
90. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-76.
91. Brennand KJ, Gage FH. Modeling psychiatric disorders through reprogramming. Dis Model Mech. 2012; 5: 26-32.
92. Kim JE, O'Sullivan ML, Sanchez CA, et al. Investigating synapse formation and function using human pluripotent stem cell-derived neurons. Proc Natl Acad Sci U S A. 2011; 108: 3005-10.
93. Marchetto MC, Carromeu C, Acab A, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. 2010; 143: 527-39.
94. Cheung AY, Horvath LM, Grafodatskaya D, et al. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum Mol Genet. 2011; 20: 2103-15.